Genentech, Chiron Settle Herceptin Patent Dispute

Law360, New York (August 3, 2005, 12:00 AM EDT) -- Biotech companies Genentech, Inc. and Chiron have quietly settled the remaining patent disputes in a $300 million lawsuit over Genentech's metastatic breast cancer drug, Herceptin (Trastuzumab).

The deal was disclosed Tuesday by Genentech in a regulatory filing to the U.S. Securities and Exchange Commission.

Genentech and Chiron settled their dispute in June, ending both interference proceedings at the U.S. Patent & Trademark Office and a lawsuit that had been appealed to the U.S. Court of Appeals for the Federal Circuit.

“Under the settlement agreement, Chiron has...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.